Articles tagged with Melanoma
PET scans improved detecting distant metastases with an accuracy of 85%, compared to 55% for current standard diagnostics. The technique also showed high accuracy in diagnosing locoregional disease, surpassing current practice by 24 percentage points.
The combination of BAY 43-9006 and standard chemotherapy showed durable partial responses in 40% of patients with advanced metastatic melanoma. The study demonstrated anti-tumor activity that was not solely dependent on a BRAF gene mutation, offering new hope for treatment options.
A phase II multicenter study evaluated a multiepitope CD8 T-cell vaccine for metastatic melanoma patients, demonstrating an immune response associated with longer survival. The vaccine showed promising results in stimulating an immune response, but no correlation was found with clinical tumor responses.
Researchers found tumor disappearance and shrinking in four out of nine patients with advanced melanoma treated with CP-675,206. The antibody works by blocking a negative regulator of the immune system, allowing it to attack cancer cells. A Phase II study is now underway to further investigate the treatment.
Researchers discovered feasible chemotherapy combinations that include trastuzumab for HER2-positive advanced breast cancer, with higher overall response rates and lower cardiac dysfunction. Two phase II clinical trials showed promising results, paving the way for future randomized phase III trials.
Researchers found that digital photographs improved detection of new or changed moles, increasing accuracy by over 10% compared to skin self-examinations alone. Baseline photography may effectively improve diagnostic accuracy in patients performing skin self-examinations.
The American College of Physicians released guidelines for treating atrial fibrillation, an abnormal heart rhythm that can lead to stroke if uncontrolled. Researchers also reviewed 18 studies on melanoma and sunscreen use, finding no link between the two conditions.
A new study published in the Journal of Clinical Oncology found that low-dose interferon therapy did not extend overall or recurrence-free survival in high-risk melanoma patients. The trial involved 674 patients and found that both groups experienced similar rates of disease recurrence and mortality.
A recent study has identified a genetic risk factor for malignant melanoma in men, highlighting the importance of faulty genes in the development of the disease. The study found that variants in the BRAF gene are more common in people with melanoma, particularly in men.
A new peptide-based vaccine has shown promising results in treating advanced melanoma by inducing a strong immune response in patients. The vaccine, which includes granulocyte macrophage-colony stimulating factor (GMCSF), resulted in significant tumor regressions and stable disease in some patients.
The American Academy of Ophthalmology has published several new studies on various eye conditions, including amblyopia, glaucoma, and corneal surgery. Researchers have explored the effectiveness of patching regimens for treating severe amblyopia in children and found promising results.
Researchers developed a new method to detect melanoma in lymph nodes using molecular analysis, revealing 25% of cancer-free patients had undetectable metastases. The study found patients with multiple markers were more likely to develop recurrence and die from the disease.
A study by cancer nurse Kerry Guile found that even oncologists and cancer nurses with high knowledge of sun protection were not acting on it. The sample size was 340 people, including medical students and non-oncology nurses, who scored highly on sun protective behavior.
Experts warn that taxing tanning may lead to increased use of indoor tanning beds among teens, who already receive too little UV light. The lack of proper sunscreen use is a major concern for public health.
Researchers are exploring alternative methods to conventional medical care for treating women's health issues, antibiotic-resistant infections, melanomas, and coronary heart disease. Nutritional and botanical therapies are being investigated as potential alternatives to traditional treatments.
Researchers found NRAS mutations in 95% of primary hereditary melanomas, but only 10% of sporadic melanomas. The study suggests a link between UV light exposure and the activation of NRAS mutations in early stages of melanoma development.
A phase II study of a multiepitope CD8 T-cell vaccine has demonstrated promising results, inducing an immune response in 32% of patients with metastatic melanoma. The vaccine showed significant correlations with non-progression of disease and longer survival rates.
A new study suggests that PTEN dysfunction is responsible for 30-60% of melanomas and offers a potential therapeutic approach to kill cancer cells. The introduction of PTEN into melanoma cells could be a useful treatment option, but the cancer cells may eventually learn to evade this approach.
A Rutgers researcher has discovered a gene that causes melanoma by expressing differently in skin cells compared to brain cells. The finding provides new insights into the disease's development and could lead to more targeted treatments.
Researchers at Memorial Sloan-Kettering Cancer Center have developed a DNA-based vaccine that triples the survival rate for dogs with advanced melanoma. The vaccine, tested in nine dogs with no side effects, shows promise for treating this aggressive cancer in humans.
Researchers have discovered a specific molecular pathway within cells that becomes mutated by ultraviolet light exposure, accelerating melanoma development. The study's findings suggest a rational method for risk stratification and screening of atypical skin moles, which could help identify patients with high-risk profiles.
A new study reveals that sentinel lymph node mapping can be safely performed on patients with melanoma in the delicate head and neck area, allowing for early detection of cancer spread. The technique has been shown to accurately stage patients and identify those who need further treatment, potentially improving survival rates.
A recent study by the American Association for Cancer Research found that patients with advanced melanoma expressing higher levels of melanoma-associated antigens (MAAs) experienced significantly improved survival outcomes. The study suggests that these tumors may be more responsive to immunotherapy, such as vaccines against melanoma.
A study by Emory University scientists identified the MAP kinase signaling pathway as a key player in early melanoma development. The researchers found that this pathway is abnormally activated in early melanomas, but not in precancerous moles. This finding has implications for diagnosis and treatment of melanoma.
A study published in the Journal of the National Cancer Institute found that higher levels of the molecule HDM2 are associated with a better prognosis in patients with melanoma. Patients with high levels of HDM2 lived significantly longer after treatment than those with low levels, even ten years after diagnosis.
A study recalculated cancer incidence rates from SEER data and found significant percentage changes (3-14%) between reporting-adjusted and unadjusted rates. The authors emphasize the importance of considering these corrections to accurately monitor trends in cancer incidence.
The study found that mortality from melanoma remained relatively stable in Scotland between 1979 and 1993, with a slight decrease in women under 65. Meanwhile, the number of people diagnosed with melanoma has increased each year. The researchers attribute the decline in death rates to improved treatment seeking behavior.
A study found that genetic mutation penetrance for melanoma varies by geographic location, with higher risks in countries like the US and Australia. Researchers suggest environmental factors contribute to this variation, contradicting previous assumptions about gene mutations and their impact on disease expression.
A recent study found that most popular melanoma web sites had incomplete facts about the disease, with around one in eight sites having inaccuracies. The study suggests that Web users should be cautious when searching for health information online and guide themselves toward reputable sources.
A genetic mutation known as Id1 may help detect melanoma early, when it's still curable. High levels of Id1 are found only in the first stages of melanoma, making it a potential diagnostic marker.
Researchers found that survival rates for primary eye cancer treatments are essentially the same, with a five-year survival rate of 82% for both radiation therapy and eye removal. The study's findings expand the capability of doctors to provide accurate diagnoses and state-of-the-art treatments.
A recent study by Ohio State University found that survival rates are similar for patients with choroidal melanoma who undergo radiation therapy or have their affected eye removed. The study, which involved 1,317 patients, showed that both treatment options result in high five-year survival rates.
Researchers found that malignant melanomas often lose the protein Apaf-1, leading to resistance to chemotherapy drug adriamycin. Restoring Apaf-1 in melanoma cells rescues their ability to kill themselves in response to adriamycin.
A definitive study led by John Kirkwood at the University of Pittsburgh Cancer Institute found that high-dose interferon alfa 2b extends both overall survival and relapse-free survival in surgically treated high-risk melanoma patients. This regimen significantly outperforms a comparison vaccine, GMK, in terms of survival impact.
Researchers found a genetic signature that divides patients with advanced melanoma into subgroups, offering clues to the disease's biology. This discovery could lead to more accurate prognosis and tailored therapies.
Researchers at UCSD develop a new drug-combination therapy using tamoxifen and cisplatin, significantly improving survival rates for patients with metastatic melanoma. The treatment results in a 62% reduction in tumor recurrence after five years.
A Phase III study found that a combination of histamine dihydrochloride and lower doses of interleukin-2 improved overall survival, increased survival rates at 12, 18, and 24 months, and reduced time-to-disease-progression compared to IL-2 alone. The treatment was well-tolerated and had substantially less toxicity.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
A custom-made vaccine created from a patient's own cancer tumor cells has proven effective in prolonging the survival of patients with malignant melanoma. The vaccine resulted in a 47% five-year survival rate among 214 patients with disease spread, outperforming standard treatment.
Researchers at the Mayo Clinic found that an experimental diode laser treatment controlled cancer growth in all but one patient with melanoma in the eye. No recurrences were noted in the remaining patients during follow-up periods.
The Wistar Institute has received a five-year grant from the National Cancer Institute to develop new diagnostic tools and treatments for metastatic melanoma. The goal of this project is to improve patient outcomes by understanding the underlying molecular events that contribute to the development and progression of the disease.
A UCSF study reports that melanoma patients with cancer spread to their sentinel lymph nodes have a greater chance of experiencing disease recurrence and mortality. The study found that patients with negative SLN biopsies had lower rates of disease recurrence and mortality.
Jefferson researchers report progress in using a vaccinia-based vaccine to treat advanced melanoma, with two patients achieving complete remission. The vaccine works by boosting the immune system with granulocyte macrophage colony stimulating factor (GM-CSF), but more research is needed to enhance the treatment.
Researchers at The Wistar Institute have discovered two genes, Alphav and Beta3, that play a crucial role in melanoma development. These findings suggest that blocking the activity of the vitronectin receptor could be an effective way to prevent cancer progression.
A University of Wisconsin-Madison research team has developed a gene therapy vaccine that helps the animal's immune system recognize and attack cancer cells. The vaccine was tested on 16 dogs with advanced stages of melanoma and showed promise, with some animals living longer and tumor shrinkage in about 20 percent of cases.
A large population-based study found no relationship between sunscreen use and melanoma risk, as people's reports of sunburn histories were inconsistent. Instead, genetic characteristics such as moles and pigmentary phenotype are major determinants of melanoma risk.
Mohs surgery has shown promise in preventing melanoma recurrence, particularly in patients with lentigo-maligna tumors. The technique's precision and ability to check surgical margins may provide a better chance of getting rid of tumors and preventing recurrences while conserving tissue.
Researchers have discovered that GM-CSF, a cytokine produced by melanoma tumors, can stimulate the immune system to attack and eliminate tumor cells. Delivering GM-CSF directly to tumors may lead to effective treatment of advanced melanoma cases.
Researchers infected mouse melanocytes with a retrovirus and observed transformed cells behaving like melanoma cells. The study aims to understand the molecular mechanisms underlying melanoma in people by identifying cellular genes disturbed by the virus.
Researchers at Penn State have discovered a new gene called KiSS-1 that suppresses the metastasis of melanoma in laboratory mice. The gene, located on chromosome 1, reduces the spread of melanoma by at least 50 percent of the time and may be the most potent gene to block or suppress metastasis in human cancer.